Since trametinib robustly rescued the expression of adhesive proteins in HET cells and is an FDA-approved drug for the treatment of RAF-mutated cancers (70, 71), we investigated whether this compound could augment intercellular adhesion in SERCA2-deficient keratinocytes. The gene discussed is ATP2A2; the disease is cancer.